Literature DB >> 29462033

Low-Dose Epinephrine Plus Tranexamic Acid Reduces Early Postoperative Blood Loss and Inflammatory Response: A Randomized Controlled Trial.

Wei-Nan Zeng1, Jun-Li Liu1,2, Fu-You Wang1, Cheng Chen1, Qiang Zhou1, Liu Yang1.   

Abstract

BACKGROUND: The reductions of perioperative blood loss and inflammatory response are important in total knee arthroplasty. Tranexamic acid reduced blood loss and the inflammatory response in several studies. However, the effect of epinephrine administration plus tranexamic acid has not been intensively investigated, to our knowledge. In this study, we evaluated whether the combined administration of low-dose epinephrine plus tranexamic acid reduced perioperative blood loss or inflammatory response further compared with tranexamic acid alone.
METHODS: This randomized placebo-controlled trial consisted of 179 consecutive patients who underwent primary total knee arthroplasty. Patients were randomized into 3 interventions: Group IV received intravenous low-dose epinephrine plus tranexamic acid, Group TP received topical diluted epinephrine plus tranexamic acid, and Group CT received tranexamic acid alone. The primary outcome was perioperative blood loss on postoperative day 1. Secondary outcomes included perioperative blood loss on postoperative day 3, coagulation and fibrinolysis parameters (measured by thromboelastography), inflammatory cytokine levels, transfusion values (rate and volume), thromboembolic complications, length of hospital stay, wound score, range of motion, and Hospital for Special Surgery (HSS) score.
RESULTS: The mean calculated total blood loss (and standard deviation) in Group IV was 348.1 ± 158.2 mL on postoperative day 1 and 458.0 ± 183.4 mL on postoperative day 3, which were significantly reduced (p < 0.05) compared with Group TP at 420.5 ± 188.4 mL on postoperative day 1 and 531.1 ± 231.4 mL on postoperative day 3 and Group CT at 520.4 ± 228.4 mL on postoperative day 1 and 633.7 ± 237.3 mL on postoperative day 3. Intravenous low-dose epinephrine exhibited a net anti-inflammatory activity in total knee arthroplasty and did not induce an obvious hypercoagulable status. Transfusion values were significantly reduced (p < 0.05) in Group IV, but no significant differences were observed in the incidence of thromboembolic complications, wound score, range of motion, and HSS score among the 3 groups (p > 0.05).
CONCLUSIONS: The combined administration of low-dose epinephrine and tranexamic acid demonstrated an increased effect in reducing perioperative blood loss and the inflammatory response compared with tranexamic acid alone, with no apparent increased incidence of thromboembolic and other complications. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29462033     DOI: 10.2106/JBJS.16.01585

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  4 in total

1.  [Perioperative blood management for total hip/knee arthroplasty].

Authors:  Mingcheng Yuan; Zichuan Ding; Tingxian Ling; Zongke Zhou
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-12-15

Review 2.  Blood management in fast-track orthopedic surgery: an evidence-based narrative review.

Authors:  Federico Pennestrì; Nicola Maffulli; Paolo Sirtori; Paolo Perazzo; Francesco Negrini; Giuseppe Banfi; Giuseppe M Peretti
Journal:  J Orthop Surg Res       Date:  2019-08-20       Impact factor: 2.359

3.  Utilization of epinephrine-soaked gauzes to address bleeding from osteotomy sites in non-tourniquet total knee arthroplasty: a retrospective cohort study.

Authors:  Hongzhi Liu; Zhaohui Liu; Qidong Zhang; Wanshou Guo
Journal:  BMC Musculoskelet Disord       Date:  2020-08-25       Impact factor: 2.362

4.  The efficacy and safety of intravenous tranexamic acid in anterior cruciate ligament reconstruction: A randomized controlled trial protocol.

Authors:  Hongyao Xu; Pengcheng Xia; Xiangjie Zou; He Huang
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.